Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Molecular pathology of non-invasive urothelial carcinomas (part I)

Abstract

An international consultation on the diagnosis of non-invasive urothelial neoplasms was held in Ancona, Italy in May 2001. Besides histology and problems of classification, one group of experts (Committee no. 3) discussed the molecular pathology and cytometry of non-invasive urothelial carcinomas. In the following first part, special immunohistochemical and molecular markers for stratifications in bladder cancer were discussed including different cytokeratins (clone 34βE12, CK 20), cell proliferation markers (Ki67/MIB-1, PCNA, AgNOR, DNA-cytometry), tumor suppressor genes and oncogenes (p53, p21, erb-B2, bcl-2), different receptor expressions of epidermal growth factor and vascular endothelial growth factor and others. These molecular markers were analyzed in diagnosis of urothelial carcinomas, recurrences, progression and response to treatment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB (2001) Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World Health Organization/International Society of Urologic Pathology. Mod Pathol 14:267-272

  2. 2.

    Burkhard FC, Markwalder R, Thalmann GN, Studer UE (1997) Immunohistochemical determination of p53 overexpression-an easy and readily available method to identify progression in superficial bladder cancer? Urol Res 25[Suppl]:31-35

  3. 3.

    Caliskan M, Türkeri LN, Mansuroglu B, Toktas G, Aksoy B, Ünlüer E, Akdas A (1997) Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 79:373-377

  4. 4.

    Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A (1997) P53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol 32:229-236

  5. 5.

    Chow NH, Tzai TS, Cheng HL, Liu HS, Chan SH, Tong YC (2000) The clinical value of p21WAF1/CIP1 expression in superficial bladder cancer. Anticancer Res 20:1173-1176

  6. 6.

    Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58:1090-1094

  7. 7.

    Edwards J, Duncan P, Going JJ, Grigor KM, Watters AD, Bartlett JM (2001) Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer 85:1894-1899

  8. 8.

    Flam TA, Chopin DK, Leleu C, Abbou CC, Steg A, Desligneres S, Boccon-Gibod L (1990) Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guerin endovesical immunotherapy for superficial bladder tumors. Eur Urol 17:338-342

  9. 9.

    Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Solter JK, Huland E, Riethdorf L, Conrad S, Hammerer PG, Huland H (2001) Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 39:159-166

  10. 10.

    Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, Lavin MF (1994) Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 73:526-532

  11. 11.

    Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A (2000) Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38:287-296

  12. 12.

    Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4:829-834

  13. 13.

    Hake R, Vorreuther R, Borchmann P, Lukowsky S, Thiele J, Fischer R (1993) Monoclonal antibodies (Mib1, pC10, 486p and p53) as prognostic factors to detect recurrent transitional cell carcinoma of the bladder. Verh Dtsch Ges Pathol 77:236-240

  14. 14.

    Harnden P, Mahmood N, Southgate J (1999) Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 353: 974-977

  15. 15.

    Helpap B (1992) Grading and prognostic significance of urologic carcinomas. Urol Int 48:245-257

  16. 16.

    Helpap B (2002) The new WHO-classification of urothelial carcinomas of the urinary bladder. Verh Dtsch Ges Pathol 86:57--66

  17. 17.

    Helpap B, Köllermann J (1999) Proliferative pattern of exophytic and superficially invasive and noninvasive low-grade urothelial carcinoms. Hum Pathol 30:145-150

  18. 18.

    Helpap B, Köllermann J (2000) Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions. A contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum Pathol 31:745-759

  19. 19.

    Helpap B, Loesevitz L, Bulatko A (1994) Nucleolar and argyrophilic nucleolar organizer region counts in urothelial carcinomas with special emphasis on grade II tumors. Virchows Arch 425:265-226

  20. 20.

    Hermann GG, Horn T, Steven K (1998) The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 159:91-94

  21. 21.

    Hudson MA, Nadler RB, Swanson PE, Humphrey PA (1995) P53 protein accumulation in superficial bladder cancer: a predictor of tumor progression which is not affected by intravesical BCG therapy. J Urol 153:531

  22. 22.

    Köllermann J, Helpap B (2001) High risk superficial bladder carcinoma-pT1G3: the significance of its diagnosis on transurethral resection specimens. Urol Integr Invest 6:24-30

  23. 23.

    Krokolopoulou P, Christodoulou P, Konstatinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P (2000) Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1. Hum Pathol 31:751-760

  24. 24.

    Krüger S, Kahl M, Fabian T, Hörlin A, Herrmann G, Müller H, Schneider M (1993) Morphometrical, cytochemical and immunohistochemical studies on the proliverative activity of urinary bladder carcinoms. Verh Dtsch Ges Pathol 77:231-235

  25. 25.

    Leissner J, Hohenfellner R, Thuroff JW, Koppen C, Wolf HK (2001) Prognostic significance of histopathological grading and immunoreactivity for p53 and p21/WAF1 in grade 2 pTa transitional cell carcinoma of the urinary bladder. Eur Urol 39:438-445

  26. 26.

    Lipponen PK, Eskelinen MJ (1995) Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121:303-308

  27. 27.

    Lipponen P, Aaltomaa S, Eskelinen M (1996) Expression of the apoptosis supressing bcl-2 protein in transitional cell bladder tumours. Histopathol 28:135-140

  28. 28.

    Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma VM (1998) Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 34:237-234

  29. 29.

    Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P (1999) Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 36:393-400

  30. 30.

    Liukkonen T, Lipponen P, Raitanen M, Kaasinen E, Ala-Opas M, Rajala P, Kosma VM (2000) Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 28:285-292

  31. 31.

    Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124-1127

  32. 32.

    Moch H, Sauter G, Gudat F, Waldman F, Mihatsch MJ (1993) Ki-67-fraction, p53-alteration and numerical chromosomal aberrations (chromosomes 7 and 17) in formalin fixed bladder carcinomas. Verh Dtsch Ges Pathol 77:226-230

  33. 33.

    Offner FA, Schöfer G, Hittmair A, Öfner D, Grünewald K, Weyrer K, Mattern D, Eberle J, Mikuz G, Feichtinger H (1993) Proliferative activity and p53 expression in transitional cell carcinomas of the urinary bladder. Verh Dtsch Ges Pathol 77:241-246

  34. 34.

    Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155:105-113

  35. 35.

    Peyromaure M, Weibing S, Sebe P, Verpillat P, Toublanc M, Dauge MC, Boccon-Gibod L, Ravery V (2002) Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 59:409-413

  36. 36.

    Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, Meyer F, Fradet Y (1999) Predictive value of cell cycle markers p53, MDM 2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5:4079-4084

  37. 37.

    Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL (2002) Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 94:1677-1684

  38. 38.

    Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53-59

  39. 39.

    Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1994) Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152:388-392

  40. 40.

    Schmitz-Dräger BJ, Kushima M, Goebell P, Jax TW, Gerharz C-D, Bültel H, Schulz WA, Ebert T, Ackermann R (1997) P53 and mdm2 in the development and progression of bladder cancer. Eur Urol 32:487-493

  41. 41.

    Schmitz-Dräger BJ, Goebell P, Ebert T, Fradet Y (2000) P53 immunohistochemistry as a prognostic marker in bladder cancer: playground for urologic scientists? Eur Urol 38:691-700

  42. 42.

    Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201-205

  43. 43.

    Sgambato A, Migaldi M, Faraglia B, Garagnani L, Romano G, De Gaetani C, Ferrari P, Capelli G, Trentini GP, Cittadini A (1999) Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59:3245-3250

  44. 44.

    Shariat SF, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP (2001) E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 57:60-65

  45. 45.

    Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones PA, Skinner DG, Cote RJ (1998) Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90:1072-1079

  46. 46.

    Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P (1996) Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155:1784-1788

  47. 47.

    Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE (1994) P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 73:533-537

  48. 48.

    Toktas G, Turkeri LN, Unluer E, Atug F, Murat C, Ozveren B, Caliskan M, Akdas A (1999) Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder. Int Urol Nephrol 31:437-441

  49. 49.

    Tsukamoto M, Matsuyama H, Oba K, Yoshihiro S, Takahashi M, Naito K (2002) Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet 134:41-45

  50. 50.

    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC (1998) The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 18:4717-4721

  51. 51.

    Vatne V, Maartmann Moe H, Hoestmark J (1995) The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol 29:491-495

  52. 52.

    Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MH, Waldman FM (1995) Patterns of p53, erbB-2, and EGF-r Expression in premalignant lesions of the urinary bladder. Hum Pathol 26:970-978

  53. 53.

    Wu TT, Chen JH, Lee YH, Huang JK (2000) The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 163:758-760

  54. 54.

    Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC (1999) Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 161:792-798

Download references

Author information

Correspondence to Burkhard Helpap.

Additional information

Authors were part of Committee no. 3, International Consultation on the Diagnosis of Non-Invasive Urothelial Neoplasms, Ancona, Italy, 11-12 May 2001

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Helpap, B., Schmitz-Dräger, B.J., Hamilton, P.W. et al. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 442, 309–316 (2003). https://doi.org/10.1007/s00428-002-0748-0

Download citation

Keywords

  • Papillary bladder cancer
  • Non-invasive
  • Cell proliferation
  • Cytokeratins
  • Tumor suppressor genes